elebsiran   Click here for help

GtoPdb Ligand ID: 14728

Synonyms: ALN-81890 | BRII-835 | VIR-2218
Compound class: Nucleic acid
Comment: Elebsiran (VIR-2218) is a N-acetylgalactosamine (GalNAc)-conjugated small interfering RNA (siRNA) that is designed to target hepatitis B virus (HBV) RNA as a mechanism to combat chronic HBV infection [2]. The nucleotides are chemically modified (2'-O-methyl/2'-MOE and 2'-deoxy-2'-fluoro/2'-F monomers), with a mixed phosphorothioate/phosphate backbone.
No information available.
Summary of Clinical Use Click here for help
Elebsiran (VIR-2218) was progressed as a clinical candidate for potential to treat (and eliminate) Hepatitis B viral infection [1].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT06903338 A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection Phase 3 Interventional Vir Biotechnology, Inc.
NCT07128550 A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide Phase 3 Interventional Vir Biotechnology, Inc.
NCT03672188 Study of VIR-2218 in Healthy Subjects and Patients With Chronic Hepatitis B Phase 1/Phase 2 Interventional Vir Biotechnology, Inc. 2-3